Immunotherapy

Immunotherapy is the concept of using the immune system to treat disease, for example, developing a vaccine against cancer. Immunotherapy may also refer to the therapy of diseases caused by the immune system, allergies for example.

What is Immunotherapy?

Immunotherapy is a treatment that is designed to harness the ability of the body’s immune system to combat infection or disease.

Activation Immunotherapies

Suppression Immunotherapies

Immunotherapy: The Future of Lung Cancer Treatment?

Neoantigens' Role in Immunotherapy

Adoptive T Cell Therapy Applications

Immunotherapy and Helminthic Therapy

Adoptive T Cell Therapy Methodology

Immunotherapy: Past, Present and Future

Latest Immunotherapy News and Research

Gut bacteria may explain differences in peanut allergy reactions

One of the big mysteries in food allergy is why two people with similar levels of peanut specific antibodies can react so differently. It turns out the answer may be in the mouth and gut's bacteria.

3 Mar 2026

New collaboration explores familial inflammatory bowel disease in Saudi Arabia

Mount Sinai and King Saud University Medical City in Riyadh, Saudi Arabia, today announced a three-year collaboration aimed at better understanding why inflammatory bowel disease (IBD) runs in some Saudi families, and how that knowledge can lead to risk ascertainment, earlier diagnosis and more personalized treatment options.

3 Mar 2026

A new standard for preventing post-surgery kidney cancer relapse

Patients with a common form of kidney cancer called clear cell renal cell carcinoma (ccRCC) who have a high risk of recurrence after surgery showed significantly improved disease-free survival when treated with an oral combination regimen that includes belzutifan, a HIF-2α inhibitor, given with standard immune therapy pembrolizumab.

1 Mar 2026

Blood biomarker guides bladder-sparing treatment decisions for cancer patients

Circulating tumor DNA, or ctDNA, can predict metastatic risk in patients who receive bladder-sparing treatment for muscle-invasive bladder cancer, but it is not a good predictor of local recurrence within the bladder, according to new data presented today by Fox Chase Cancer Center researchers.

27 Feb 2026

Genomic landscape and clinicopathologic significance of POLE mutant colorectal carcinoma

DNA polymerase epsilon catalytic subunit A (POLE) gene plays a crucial role in DNA repair and chromosomal replication.

27 Feb 2026

Fifteen-year follow up reveals cure potential in follicular lymphoma

Unlike some other forms of lymphoma, advanced stage follicular lymphoma is considered incurable. But a new analysis of long-term data on patients treated for the disease years ago with standard regimens of immunotherapy and a chemotherapy combination known as CHOP suggests that many of those patients can now be considered cured.

26 Feb 2026

Combination therapy may help overcome barrier in early-stage prostate cancer treatment

A multi-institutional study led by Mayo Clinic and published in Cell Reports Medicine reports that pairing a next-generation immunotherapy with standard hormone therapy before surgery may help overcome a long-standing barrier in early-stage prostate cancer treatment.

26 Feb 2026

Early-life immune system differences drive childhood eczema risk

A team of researchers at the Icahn School of Medicine at Mount Sinai, Weill Cornell Medicine, and other institutions have uncovered a key biological explanation for why eczema so often starts in childhood.

25 Feb 2026

Next-generation CAR T therapy offers hope but faces clinical challenges

A new editorial perspective was published in Volume 17 of Oncotarget on February 20, 2026, titled "CAR-T therapy: Trailblazing CAR(ing) in cancer treatment."

25 Feb 2026

Centauri Therapeutics extends Series A to £30 M with £6 M investment from AMR Action Fund to support progression of lead clinical candidate

Centauri Therapeutics Limited ('Centauri'), an immunotherapy company with a unique and proprietary platform technology applicable across a wide range of therapeutic indications, today announced it has secured £6 M from AMR Action Fund, extending the Company's Series A round to £30 M.

24 Feb 2026

Ochsner MD Anderson Cancer Center delivers Louisiana’s first TIL therapy for melanoma

Ochsner MD Anderson Cancer Center at The Gayle and Tom Benson Cancer Center in New Orleans announces a milestone in advanced cancer treatment, as the first institution in Louisiana to provide an adult patient with tumor-infiltrating lymphocytes (TIL) therapy for advanced melanoma.

23 Feb 2026

Remote-controlled CAR T cells offer safer cancer therapy

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers.

19 Feb 2026

Protein made by stressed cancer cells helps tumors to evade immune attack

A protein made by stressed cancer cells helps lung and pancreatic tumors evade the immune system, a new study shows.

18 Feb 2026

Researchers discover a way to breach cancer’s impenetrable fortress

Researchers at Case Western Reserve University have discovered a way to breach one of cancer's most stubborn defenses: the impenetrable fortress that solid tumors build around themselves.

18 Feb 2026

Cornell study finds existing drug could boost liver cancer immunotherapy

Immunotherapy – which activates the body's own immune system to kill cancer cells – has not worked well against a rare and fatal liver cancer, but a new Cornell University study finds an existing FDA-approved drug may allow the immunotherapy to fight the cancer as intended, opening the door to a potential treatment.

17 Feb 2026

Preoperative combination treatment shows promise for some patients with pancreatic cancer

A new UCLA investigator-initiated study sponsored by the UCLA Health Jonsson Comprehensive Cancer Center has found that adding immunotherapy to standard chemotherapy before surgery is safe and shows promise for some patients with borderline-resectable pancreatic cancer, a disease that has historically been difficult to treat.

17 Feb 2026

Fred Hutch scientists reach crucial milestone in blocking Epstein Barr virus

Fred Hutch Cancer Center scientists reached a crucial milestone in blocking Epstein Barr virus (EBV), a pathogen estimated to infect 95% of the global population that is linked to multiple types of cancer, neurodegenerative diseases and other chronic health conditions.

17 Feb 2026

Chronic inflammation shapes cancer progression and immunotherapy response

Chronic inflammation is both a driver and suppressor of cancer depending on context. Key players-NF-κB, IL-6, STAT3, TAMs, MDSCs, and Tregs-orchestrate a tumor-permissive microenvironment.

16 Feb 2026

Engineered Listeria boosts innate immunity against cancer

After nearly 40 years of research on how Listeria bacteria manipulate our cells and battle our immune system to cause listeriosis, Daniel Portnoy and his colleagues have discovered a way to turn the bacteria into a potent booster of the immune system - and a potential weapon against cancer.

13 Feb 2026

Novel antibody 007 targets the elusive HIV envelope epitope

HIV-1 can be neutralized by antibodies which bind to vulnerable structures on the virus surface. One such vulnerable site is the so-called V3 glycan site of the viral envelope protein.

13 Feb 2026